文献速递治疗药物监测与药物基因组学药物相互作用抗栓抗凝管理

迈向个体化抗栓治疗:聚焦P2Y12抑制剂与直接口服抗凝药

Towards Personalized Antithrombotic Treatments: Focus on P2Y12 Inhibitors and Direct Oral Anticoagulants.
PubMed 文献 · Clin Pharmacokinet · 2019-01-01

综述聚焦P2Y12抑制剂与直接口服抗凝药的个体化用药。抗栓药常致出血或复发性缺血事件,现行个体化工具预测能力有限。文章汇总现有个体化处方策略,并评估PBPK与POPPK模型在预测血药浓度、指导剂量调整及临床落地中的价值、局限与挑战。

要点

  • 抗栓药出血与复发性缺血事件常见,一刀切策略正受质疑
  • 血药浓度与出血及复发性缺血相关,可作为个体化抓手
  • PBPK与POPPK模型可整合体外、遗传与生理数据预测个体暴露

核心结论

  • 抗栓治疗需从一刀切转向个体化,预测血药浓度可能是有效途径
  • PBPK与POPPK模型有望预测个体抗栓药血药浓度,预防临床无反应或出血
  • 现有工具预测临床事件能力有限,模型临床落地仍存局限与挑战

研究设计与样本

  • 综述,以P2Y12抑制剂和直接口服抗凝药为例回顾现有抗栓处方个体化方法
  • 汇总现有针对P2Y12抑制剂和直接口服抗凝药的PBPK与POPPK模型
  • 讨论模型在临床实施的可能情景、主要局限与挑战

主要发现

  • 相当比例服用抗栓药的患者仍发生出血或复发性缺血事件
  • 抗栓药血药浓度与出血和复发性缺血相关
  • PBPK与POPPK模型可整合体外实验数据与患者人口学、遗传和生理在体数据刻画剂量-浓度关系

临床怎么用

  • 可借助PBPK与POPPK模型预测个体抗栓药暴露,辅助制定适配特定人群特征的剂量
  • 目标浓度干预可作为个体化抗栓处方的思路,用于预防临床无反应或出血

局限性

  • 现有可用个体化工具有限,仅中等程度预测临床事件或影响临床结局
  • PBPK与POPPK模型在临床实施中仍存在主要局限与挑战

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Oral anticoagulants and antiplatelet drugs are commonly prescribed to lower the risk of cardiovascular diseases, such as venous and arterial thrombosis, which represent the leading causes of mortality worldwide. A significant percentage of patients taking antithrombotics will nevertheless experience bleeding or recurrent ischemic events, and this represents a major public health issue. Cardiovascular medicine is now questioning the one-size-fits-all policy, and more personalized approaches are increasingly being considered. However, the available tools are currently limited and they are only moderately able to predict clinical events or have a significant impact on clinical outcomes. Predicting concentrations of antithrombotics in blood could be an effective means of personalization as they have been associated with bleeding and recurrent ischemia. Target concentration interventions could take advantage of physiologically based pharmacokinetic (PBPK) and population-based pharmacokinetic (POPPK) models, which are increasingly used in clinical settings and have attracted the interest of governmental regulatory agencies, to propose dosages adapted to specific population characteristics. These models have the benefit of combining parameters from different sources, such as experimental in vitro data and patients' demographic, genetic, and physiological in vivo data, to characterize the dose-concentration relationships of compounds of interest. As such, they can be used to predict individual drug exposure. In the near future, these models could therefore be a valuable means of predicting personalized antithrombotic blood concentrations and, hopefully, of preventing clinical non-response or bleeding in a given patient. Existing approaches for personalization of antithrombotic prescriptions will be reviewed using practical examples for P2Y12 inhibitors and direct oral anticoagulants. The review will additionally focus on the existing PBPK and POPPK models for these two categories of drugs. Lastly, we address potential scenarios for their implementation in clinics, along with the main limitations and challenges.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Terrier J, Daali Y, Fontana P, et al. Towards Personalized Antithrombotic Treatments: Focus on P2Y12 Inhibitors and Direct Oral Anticoagulants. Clin Pharmacokinet. 2019. PMID: 31250210. doi:10.1007/s40262-019-00792-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。